American Cancer Society. Cancer facts & figures 2022. Atlanta: American Cancer Society; 2022. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/2022-cancer-facts-and-figures.pdf.

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015;193:1163.

Article  PubMed  Google Scholar 

Padhani AR, Petralia G, Sanguedolce F. Magnetic resonance imaging before prostate biopsy: time to talk. Eur Urol. 2016;69:1–3.

Article  PubMed  Google Scholar 

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815–22.

Article  PubMed  Google Scholar 

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767–77.

Article  PubMed  PubMed Central  Google Scholar 

Park KJ, Choi SH, Lee JS, Kim JK, Kim MH, Jeong IG. Risk stratification of prostate cancer according to PI-RADS® Version 2 categories: meta-analysis for prospective studies. J Urol. 2020;204:1141–9.

Article  PubMed  Google Scholar 

Oerther B, Engel H, Bamberg F, Sigle A, Gratzke C, Benndorf M. Cancer detection rates of the PI-RADSv2.1 assessment categories: systematic review and meta-analysis on lesion level and patient level. Prostate Cancer Prostatic Dis. 2021. https://doi.org/10.1038/s41391-021-00417-1.

Kinnaird A, Brisbane W, Kwan L, Priester A, Chuang R, Barsa DE, et al. A prostate cancer risk calculator: use of clinical and magnetic resonance imaging data to predict biopsy outcome in North American men. Can Urol Assoc J. 2022;16:E161.

PubMed  Google Scholar 

Alberts AR, Roobol MJ, Verbeek JFM, Schoots IG, Chiu PK, Osses DF, et al. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European randomized study of screening for prostate cancer risk calculators. Eur Urol. 2019;75:310–8.

Article  PubMed  Google Scholar 

Patel HD, Koehne EL, Shea SM, Fang AM, Gerena M, Gorbonos A, et al. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators. BJU Int. 2022. https://pubmed-ncbi-nlm-nih-gov.ezproxy.galter.northwestern.edu/35733400/.

Patel HD, Koehne EL, Shea SM, Bhanji Y, Gerena M, Gorbonos A, et al. Risk of prostate cancer for men with prior negative biopsies undergoing magnetic resonance imaging compared with biopsy-naive men: a prospective evaluation of the PLUM cohort. Cancer. 2022;128:75–84. https://onlinelibrary-wiley-com.ezproxy.galter.northwestern.edu/doi/full/10.1002/cncr.33875.

Article  PubMed  Google Scholar 

Eyrich NW, Morgan TM, Tosoian JJ. Biomarkers for detection of clinically significant prostate cancer: contemporary clinical data and future directions. Transl Androl Urol. 2021;10:3091–103. https://pubmed-ncbi-nlm-nih-gov.ezproxy.galter.northwestern.edu/34430413/.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, et al. Prostate Health Index (phi) improves multivariable risk prediction of aggressive prostate cancer. BJU Int. 2017;120:61.

Article  CAS  PubMed  Google Scholar 

Konety B, Zappala SM, Parekh DJ, Osterhout D, Schock J, Chudler RM, et al. The 4Kscore® test reduces prostate biopsy rates in community and academic urology practices. Rev Urol. 2015;17:231.

PubMed  PubMed Central  Google Scholar 

Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68:1045–53.

Article  PubMed  Google Scholar 

Shariat SF, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res. 2008;14:4400–7.

Article  CAS  PubMed  Google Scholar 

Chun FK, Karakiewicz PI, Briganti A, Walz J, Kattan MW, Huland H, et al. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. BJU Int. 2007;99:794–800.

Touijer K, Scardino PT. Nomograms for staging, prognosis, and predicting treatment outcomes. Cancer. 2009;115:3107–11.

Article  PubMed  Google Scholar 

Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Han LC, Thompson RH, et al. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a National Survey of Radiation Oncologists and Urologists. J Urol. 2013;189:2092–8. https://doi.org/10.1016/j.juro.2012.11.174.

Article  PubMed  Google Scholar 

Eklund M, Jäderling F, Discacciati A, Bergman M, Annerstedt M, Aly M, et al. MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med. 2021;385:908–20. https://doi.org/10.1056/NEJMoa2100852.

Article  PubMed  Google Scholar 

Nordström T, Discacciati A, Bergman M, Clements M, Aly M, Annerstedt M, et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 2021;22:1240–9.

Article  PubMed  Google Scholar 

Wagaskar VG, Sobotka S, Ratnani P, Young J, Lantz A, Parekh S, et al. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer. Cancer Rep. 2021;4:1–9.

Google Scholar 

Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, et al. Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the prostate magnetic resonance imaging outcome database (PROMOD). Eur Urol Oncol. 2021;4:971–9.

Article  PubMed  Google Scholar